Subcutaneous · GLP-1 agonist
Albiglutide
41 trials in this molecule. Source: ClinicalTrials.gov, as of July 6, 2026.
Trials
41
Ongoing
3
Recruiting
0
Completed
33
Sites
1,396
Countries
41
Endpoints
530
Composite endpoints
43
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
9
Phase 2
7
Phase 3
15
Phase 4
6
Not applicable
4
Trials by status
Not yet recruiting
1
Active, not recruiting
2
Completed
33
Terminated
3
Withdrawn
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
190
Safety / tolerability / PK
175
Weight & body composition
39
Cardiometabolic biomarkers
27
Cardiovascular outcomes
23
Renal / kidney
23
Other clinical outcomes
18
Patient-reported / QoL
16
Other (unclassified)
15
Heart failure
3
MASH / liver
1
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
50
Fasting glucose, changeGlycemic
38
Body weight, absolute change (kg)Weight
37
HbA1c <6.5% achievementGlycemic
23
HbA1c <7.0% achievementGlycemic
16
Documented hypoglycemiaSafety/PK
14
Postprandial glucoseGlycemic
11
Plasma concentration (steady state)Safety/PK
9
Heart rate, changeBiomarker
8
Treatment-emergent AEs (any)Safety/PK
8
Serious AEs (any)Safety/PK
7
AUC₀-∞Safety/PK
7
Discontinuation due to AESafety/PK
6
C-peptide AUCGlycemic
5
NauseaSafety/PK
5
Immunogenicity (ADA)Safety/PK
5
Expanded / custom MACE compositeCV
4
eGFR, changeRenal
4
CmaxSafety/PK
4
All-cause deathCV
3
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
41 of 41
Showing 1-25 of 41 trials